Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-Ignite: Rocatinlimab monotherapy in moderate to severe atopic dermatitis
CTR20231925Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Jul 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20231925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231925.